Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 17/20 | 0.81 |
| ▸ | PDE4A | P27815 | 15/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.66 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.66 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15270505 | 0.89 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4CCYP2B6 | |
| SCHEMBL2908650 | 0.87 | PDE4D (0.81) | PDE4DPDE4APDE4BPDE4CCYP2B6 | |
| SCHEMBL30614194 | 0.87 | PDE4D (0.81) | PDE4DPDE4APDE4BPDE4CCYP2B6 | |
| SCHEMBL7357641 | 0.84 | PDE4D (0.83) | PDE4DPDE4APDE4BPDE4CCYP2B6 | |
| SCHEMBL7353637 | 0.83 | PDE4D (0.81) | PDE4DPDE4APDE4BPDE4CCYP2B6 | |
| SCHEMBL987384 | 0.82 | PDE4B (0.80) | PDE4DPDE4APDE4BPDE4CCYP2B6 | |
| SCHEMBL7534706 | 0.82 | PDE4D (0.80) | PDE4DPDE4APDE4BPDE4CCYP2B6 | |
| SCHEMBL7425558 | 0.82 | PDE4D (0.72) | PDE4DPDE4APDE4BPDE4CCYP2B6 | |
| SCHEMBL30084836 | 0.82 | PDE4D (0.80) | PDE4DPDE4APDE4BPDE4CCYP2B6 | |
| SCHEMBL30084831 | 0.82 | PDE4D (0.80) | PDE4DPDE4APDE4BPDE4CCYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464651-B1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| WO-2011018510-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | PDE4D 5/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.